Patents by Inventor Neil Cashman
Neil Cashman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9809620Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.Type: GrantFiled: April 29, 2014Date of Patent: November 7, 2017Assignee: University of SaskatchewanInventors: Kristen Marciniuk, Ryan Taschuk, Scott Napper, Andrew Potter, Neil Cashman
-
Publication number: 20170192020Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: ApplicationFiled: March 7, 2017Publication date: July 6, 2017Inventor: Neil Cashman
-
Patent number: 9625476Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: GrantFiled: July 31, 2014Date of Patent: April 18, 2017Assignee: PROMIS NEUROSCIENCES INC.Inventor: Neil Cashman
-
Publication number: 20170008955Abstract: Provided herein are humanized antibodies or antigen-binding fragments thereof, that can bind to a cyclic peptide comprising the amino acid sequence SNK, wherein the K (Lysine) is solvent-accessible and methods of treating and/or preventing amyloid-beta associated diseases such as Alzheimer's disease.Type: ApplicationFiled: February 3, 2015Publication date: January 12, 2017Inventors: Cory Nykiforuk, Darrell Johnstone, Neil Cashman
-
Patent number: 9523697Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent.Type: GrantFiled: October 22, 2010Date of Patent: December 20, 2016Assignee: PROMIS NEUROSCIENCES Inc.Inventors: Neil Cashman, Marty Lehto
-
Patent number: 9507012Abstract: Examples of determining the position of a mobile device within a structure are disclosed. In one example implementation according to aspects of the present disclosure, a computing device may include a processor and a memory. The computing device may further include an extraction module stored in the memory and executing on the processor to extract from a location-based service data stream a signal measurement of the path loss between a mobile device and a plurality of radio nodes distributed throughout a structure. The computing device may also include a positioning determining module stored in the memory and executing on the processor to determine the position of the mobile device within the structure using a known location for each of the plurality of radio nodes distributed throughout the structure by performing a linear optimization using the extracted signal measurement of the path loss.Type: GrantFiled: July 31, 2013Date of Patent: November 29, 2016Assignee: Hewlett Packard Enterprise Development LPInventors: John T. Brassil, Lee Edward Fuller, Christopher Thomas Pearson, Neil Cashman
-
Publication number: 20160187459Abstract: Examples of determining the position of a mobile device within a structure are disclosed. In one example implementation according to aspects of the present disclosure, a computing device may include a processor and a memory. The computing device may further include an extraction module stored in the memory and executing on the processor to extract from a location-based service data stream a signal measurement of the path loss between a mobile device and a plurality of radio nodes distributed throughout a structure. The computing device may also include a positioning determining module stored in the memory and executing on the processor to determine the position of the mobile device within the structure using a known location for each of the plurality of radio nodes distributed throughout the structure by performing a linear optimization using the extracted signal measurement of the path loss.Type: ApplicationFiled: July 31, 2013Publication date: June 30, 2016Inventors: John T. BRASSIL, Lee Edward FULLER, Christopher Thomas PEARSON, Neil CASHMAN
-
Patent number: 9376476Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.Type: GrantFiled: May 12, 2015Date of Patent: June 28, 2016Assignee: University of SaskatchewanInventors: Scott Napper, Peter Hedlin, Philip Griebel, Lorne Babiuk, Neil Cashman, Avijit Chakrabartty, Andrew Potter
-
Publication number: 20160130363Abstract: There are provided herein novel monoclonal antibodies that selectively bind and/or activate TrkC receptors, pharmaceutical compositions thereof and the use thereof for treating or preventing conditions which require activation of TrkC, such as amyotrophic lateral sclerosis and other neurodegenerative conditions and motor neuron diseases. The monoclonal antibodies are useful to screen for agents that share the same binding epitope on the TrkC receptor.Type: ApplicationFiled: October 27, 2015Publication date: May 12, 2016Inventors: Horacio Uri Saragovi, Veronique Guillemard, Neil Cashman
-
Patent number: 9200080Abstract: There are provided herein novel monoclonal antibodies that selectively bind and/or activate TrkC receptors, pharmaceutical compositions thereof and the use thereof for treating or preventing conditions which require activation of TrkC, such as amyotrophic lateral sclerosis and other neurodegenerative conditions and motor neuron diseases. The monoclonal antibodies are useful to screen for agents that share the same binding epitope on the TrkC receptor.Type: GrantFiled: November 30, 2010Date of Patent: December 1, 2015Inventors: Horacio Uri Saragovi, Véronique Guillemard, Neil Cashman
-
Publication number: 20150313976Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.Type: ApplicationFiled: May 12, 2015Publication date: November 5, 2015Applicant: University of SaskatchewanInventors: Scott Napper, Peter Hedlin, Philip Griebel, Lorne Babiuk, Neil Cashman, Avijit Chakrabartty, Andrew Potter
-
Patent number: 9056918Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.Type: GrantFiled: April 23, 2009Date of Patent: June 16, 2015Assignee: University of SaskatchewanInventors: Scott Napper, Peter Hedlin, Philip Griebel, Lorne Babiuk, Neil Cashman, Avijit Chakrabartty, Andrew Potter
-
Publication number: 20150004185Abstract: Prion peptides comprising prion epitopes and fusions thereof, that display enhanced immunogenicity are described. Also described are methods of treating and diagnosing prion disease.Type: ApplicationFiled: April 29, 2014Publication date: January 1, 2015Applicant: University of SaskatchewanInventors: Kristen Marciniuk, Ryan Taschuk, Scott Napper, Andrew Potter, Neil Cashman
-
Publication number: 20140335538Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: ApplicationFiled: July 31, 2014Publication date: November 13, 2014Inventor: Neil Cashman
-
Patent number: 8828389Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: GrantFiled: December 7, 2011Date of Patent: September 9, 2014Assignee: Amorfix Life Sciences Ltd.Inventor: Neil Cashman
-
Publication number: 20140004119Abstract: There are provided herein novel monoclonal antibodies that selectively bind and/or activate TrkC receptors, pharmaceutical compositions thereof and the use thereof for treating or preventing conditions which require activation of TrkC, such as amyotrophic lateral sclerosis and other neurodegenerative conditions and motor neuron diseases. The monoclonal antibodies are useful to screen for agents that share the same binding epitope on the TrkC receptor.Type: ApplicationFiled: November 30, 2010Publication date: January 2, 2014Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITYInventors: Horacio Uri Saragovi, Véronique Guillemard, Neil Cashman
-
Publication number: 20120077212Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: ApplicationFiled: December 7, 2011Publication date: March 29, 2012Applicant: AMORFIX LIFE SCIENCESInventor: Neil Cashman
-
Patent number: 8075891Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: GrantFiled: June 2, 2010Date of Patent: December 13, 2011Assignee: Amorfix Life Sciences Ltd.Inventor: Neil Cashman
-
Publication number: 20110135673Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.Type: ApplicationFiled: June 2, 2010Publication date: June 9, 2011Applicant: AMORFIX LIFE SCIENCESInventor: Neil Cashman
-
Publication number: 20110124018Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent.Type: ApplicationFiled: October 22, 2010Publication date: May 26, 2011Applicant: AMORFIX LIFE SCIENCES LTD.Inventors: Neil Cashman, Marty Lehto